

29 September 2026

ZYPINE ODT (Olanzapine) 5 mg Orodispersible Tablets
– Alternative Registered Foils

Dear Healthcare Professional,

We are writing to provide you with an important update regarding ZYPINE ODT (Olanzapine) 5 mg Orodispersible Tablets sponsored by Viatris Ltd.

To ensure continuous supply, a labelling exemption has been granted by Medsafe for Zypine ODT 5 mg Orodispersible Tablets to allow the supply of product manufactured for the Czech Republic market into New Zealand for a short period.

The tablets produced for the Czech market are identical to the New Zealand product, with no difference in the formulation or appearance.

The blister strips from the Czech market will be placed into the existing New Zealand-registered cartons and the following is of note:

- The foil text is not in English, and
- The trade name printed on the foil states ‘Olanzapin Mylan’.

Both New Zealand and Czech blisters may be distributed concurrently in the short term.

Images of the Czech blister foils are provided in the table overleaf.

Adverse Event Reporting & Medical Enquiries

Please report any suspected adverse events via email to Medinfo_anz@viatris.com. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) online at <https://pophealth.my.site.com/carmreportnz/s/> or by email to CARMreport@health.govt.nz. Please direct any medical enquiries to Viatris or report any suspected adverse drug reactions to Viatris via telephone on 0800 168 169 or by email at medinfo_anz@viatris.com.

Yours sincerely,



Sue Lyn Lim
Senior Medical Affairs Specialist

Foil Overview

Existing Registered Foil	Alternative Registered Foils (temporary availability)
Zypine ODT 5 mg 	Olanzapin Mylan 5 mg 